The South Korean company plans to use the funds to advance the development of endometriosis therapy, merigolix.South Korean TiumBio has raised KRW20bn ($12m) through stock financing to fund the development of its clinical programmes.The capital would be primarily used to support the clinical development of its three lead candidates – merigolix (TU2670), TU2218 and TU7710, […]
